Clinical Trial Detail

NCT ID NCT01182168
Title Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

urinary system cancer

Therapies

Cisplatin + Everolimus + Gemcitabine

Age Groups: adult

No variant requirements are available.